<DOC>
	<DOCNO>NCT01399242</DOCNO>
	<brief_summary>The primary objective demonstrate superiority everolimus plus Myfortic® plus corticosteroid follow CNI withdrawal week 16 compare tacrolimus plus Myfortic® plus corticosteroid measure change calculate Glomerular Filtration Rate ( cGFR ) baseline month 12 . The key secondary objective demonstrate non-inferiority biopsy-proved acute rejection ( BPAR ) , graft loss , death loss follow-up ( composite endpoint ) month 12 patient switch everolimus plus Myfortic® plus corticosteroid follow CNI withdrawal Week 16 compare patient maintain tacrolimus plus Myfortic® plus corticosteroid . Patients submit monthly GFR determination , group comparison , GFR measure month 12 month 24 renal transplantation use .</brief_summary>
	<brief_title>Efficacy Certican® Combination With Myfortic® Renal</brief_title>
	<detailed_description>1.Forty patient select 16 week renal transplantation 20 patient allocate study arm . The allocation do randomly provide similar epidemiological characteristic respect gender , age , renal function co morbidity two group . The informed consent obtain interview involve researcher patient protocol explain . 1.1 Study protocol Patients renal transplant unit Sao Jose University Hospital sign inform consent fulfill inclusion/exclusion criterion enrol study . The main population low-risk kidney transplant recipient define follow : primary transplant , patient older 18 year old recipient first kidney transplantation live donor PRA &lt; 10 % , use tacrolimus , EC-MPS , steroid primary immunosuppression , without delay graft function stable renal function 3 month transplantation . Patients fulfill inclusion criterion agree participate study CNI withdrawn immunosuppressive regimen base everolimus . The switch do follow : patient ' therapy replace CNI-based everolimus-based immunosuppression . Everolimus introduce day 1 dose 2 mg/day ( 1mg bid ) , everolimus trough level obtain day 3 onwards C0 reach target three consecutive day . Through level adjust achieve 6-10ng/ml . Thereafter , target level reach , measurement perform weekly 4 week every 2 week 8 week conversion . In parallel , CNI dose reduced 50 % day 1 another 25 % day 7 . The CNI withdrawn day 14 target level everolimus obtain . EC-MPS unchanged day 14 conversion , thereafter decrease necessary 1440mg 1080mg/day . The dose EC-MPS 1080 mg/day . Corticosteroids would unchanged . A protocol renal biopsy perform end study , 12 month transplantation . A per-operatory biopsy baseline perform , since routine practice transplant center patient low immunological risk . 1.3- Inclusion criterion 1.3.1- Men woman 18-70 year old 1.3.2- Receptors first living-donor kidney allograft 1.3.3- Patients must tacrolimus+myfortic regimen least 2 week prior randomization 1.4- Exclusion criterion 1.4.1- Patients evidence acute rejection follow transplantation time randomization 1.4.2- GFR ≤ 35 ml/min 1.4.3- Proteinuria &gt; 800 mg/day 1.4.4- Recipients multiple organ transplant 1.4.5- Chronic hepatic failure 1.4.6- Asymptomatic bacteriuria 1.4.7- Creatinine ≥ 2mg/dL CNI withdrawn time 1.4.8- Proteinuria ≥ 1g/24h CNI withdrawn time 1.4.9- Presence uncontrolled hypercholesterolemia ( ≥ 350 mg/dL , ≥ 9.1 mmol/L ) 1.4.10- Hypertriglyceridemia ( ≥ 500 mg/dL , ≥ 5.6 mmol/L ) 1.5- Statistical analysis This investigational interventional study , two-arms , evaluate renal function composite efficacy end-point conversion immunosuppressive regime tacrolimus everolimus . As pilot study , sample size estimate 20 patient arm ( total = 40 patient ) accord number kidney transplant usually perform hospital . For GRF evaluation ANOVA use . A difference 5-10ml/min GRF expect compare study control group . The incidence acute rejection analyze chi-square .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Men woman 1870 year old Receptors first livingdonor kidney allograft Patients must tacrolimus+myfortic regimen least 2 week prior randomization Patients evidence acute rejection follow transplantation time randomization GFR ≤ 35 ml/min Proteinuria &gt; 800 mg/day Recipients multiple organ transplant Chronic hepatic failure Asymptomatic bacteriuria Creatinine ≥ 2mg/dL CNI withdrawn time Proteinuria ≥ 1g/24h CNI withdrawn time Presence uncontrolled hypercholesterolemia ( ≥ 350 mg/dL , ≥ 9.1 mmol/L ) Hypertriglyceridemia ( ≥ 500 mg/dL , ≥ 5.6 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Disorder Related Renal Transplantation</keyword>
</DOC>